John McHutchison, outgoing Assembly Biosciences CEO
December 19, 2022 11:19 AM ESTUpdated 03:24 PM
R&D

Emerg­ing from he­pati­tis B flops, As­sem­bly Bio show­cas­es ear­ly da­ta on next-gen drugs

Amber Tong

John McHutchi­son will be leav­ing As­sem­bly Bio­sciences with a glimpse at the fu­ture he promised af­ter the biotech ran in­to mul­ti­ple set­backs in its pur­suit …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times